Megaloblastic anaemia due to folate deficiency is not an accepted complication of sulphasalazine treatment, although there are a few case reports of the association.'-4 Two patients who developed macrocytic megaloblastic anaemia due to folate deficiency during treatment with suIphasalazine prompted this study. A group of patients with ulcerative colitis was investigated to assess the incidence and cause of folate deficiency and the role of sulphasalazine in aetiology.
Methods

PATIENTS
Eighty-three outpatients with histologically proven ulcerative colitis who attended consecutive gastrointestinal outpatient clinics at Northwick Park Hospital had samples taken for a full blood count, reticulocyte count, haptoglobins, B12, folate, red cell folate, and biochemical screen including iron and iron binding capacity. Three patients were receiving folic acid supplements and their results were subsequently excluded. Sixty (75%) of the remaining 80 patients were being treated with sulphasalazine in doses of 2-4g/day. Six of the remaining 20 (25%) patients were newly
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Two patients who were recognised before the study started and two patients identified by the study, all with megaloblastic anaemia or macrocytos,is due to folate deficiency which developed during treatment with sulphasalazine, underwent detailed studies as inpatients on a metabolic ward to assess the causes of their folate deficiency. These studies included two measurements of folate absorption, one initially while the patient was being treated with sulphasalazine and one at least two months after treatment was stopped; jejunal biopsy at the time of each folate absorption study; and dietary assessment at the time of the first absorption study.
Folate absorption was also measured in six newly diagnosed patients, and repeated after three months' treatment with sulphasalazine. In one patient it was also measured with the first dose of sulphasalazine. All patients underwent jejunal biopsies to exclude coeliac disease.
Haematological and biochemical parameters were measured routinely in the hospital laboratories. Red cell indices were corrected for trapped plasma. Serum B12, folate, and red cell folate were assayed microbiologically.
Folate absorption was measured directly. Faecal excretion of a tritium-labelled physiological folate derivative, 5-methyltetrahydrop-teroylglutamic acid, given orally in a physiological dose of 3jgg/kg, was measured using the method described by Steytler. 
Results
OUTPATIENT SURVEY
Eighteen (22.5%) of the patients were macrocytic with a mean cell volume (MCV) above the upper limit of normal, 92fl. All these patients were being treated with sulphasalazine (P<0.05). The mean MCV was higher (P<0-001) in the treated group, but the mean MCV of both groups fell within the normal range (Fig. 1) .
Twenty-five of 59 (42.4%) patients in the group treated with sulphasalazine had a raised reticulocyte count (normal range <2%) compared with one of 15 (67%) in the untreated group (P<0.05). The highest reticulocyte count recorded was 4.2%. Reticulocyte count was directly (P<0001) related to the dose of sulphasalazine ( 16 .1 % ± 6.6% (SD) (P<001) (Fig. 2) .
In one patient folate absorption measured with the first dose of sulphasalazine was 70% compared with 89% before treatment and 77% after three months' treatment. Table 2 shows the severity of the haematological abnormalities which developed with sulphasalazine in the four folate deficient patients. Patient 1 was treated with folic acid in a pharmacological dose of 5 mg three times a day while sulphasalazine was continued. Her haematological abnormalities resolved completely. The other three patients did not receive folate supplements, but stopped sulphasalazine. Their haematological abnormalities also resolved completely. Figure 3 shows serial results from patient 2 to illustrate the rate of development of haematological abnormalities with su4phasalazine and the rate of resolution after the drug is stopped. This patient's reticulocyte count was 3.2% when his None of the six newly diagnosed patients had evidence of coeliac disease but three (50%) had non-specific minor abnormalities on their initial jejunal biopsies. All three had raised intraepithelial lymphocyte counts and two also had subjective and morphometric evidence of a mild partial villous atrophy. Changes in all but one patient had resolved completely when the biopsies were repeated.
OTHER STUDIES
Three newly diagnosed patients had a low red cell foilate, but after three months' treatment with sulphasalazine in maximum tolerated dose (2-4 g/day) the level was normal in two of these patients, despite further impairment in folate absorption.
Discussion
The incidence of significant folate deficiency in patients with ulcerative colitis attending the gastroenterological clinic at Northwick Park Hospital is low. Only 2.5 % (two of 80) Macrocytosis is an unreliable indicator of folate deficiency in patients receiving sulphasalazine. Minor haemolysis is a well-recognised doserelated effect of the drug.8 This results in a higher proportion of younger, larger cells in the circulation reflected by a rise in MCV and sometimes an increased reticulocyte count. A higher proportion of our patients receiving sulphasalazine had a raised reticulocyte count, compared with the untreated group. Haptoglobin estimation was less sensitive in detecting these minor degrees of haemolysis which occurred with sulphasalazine. Conversely, coincidental iron deficiency may mask the effect of folate deficiency on MCV in patients with active disease. 
